Cardiff Oncology (NASDAQ:CRDF – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. According to Zacks, “Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company’s product […]
Cardiff Oncology (NASDAQ:CRDF – Get Rating) had its price objective dropped by investment analysts at Piper Sandler from $20.00 to $7.00 in a report released on Friday, The Fly reports. Piper Sandler’s price objective points to a potential upside of 442.64% from the stock’s previous close. A number of other brokerages have also recently issued […]
Cardiff Oncology (NASDAQ:CRDF – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company’s product pipeline consists of a […]
Equities analysts expect that Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Rating) will post earnings per share of ($0.25) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Cardiff Oncology’s earnings, with estimates ranging from ($0.28) to ($0.22). Cardiff Oncology reported earnings of ($0.17) per share during the same quarter last […]
Krystal Biotech (NASDAQ:KRYS – Get Rating) and Cardiff Oncology (NASDAQ:CRDF – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership. Volatility & Risk Krystal Biotech has a beta of […]